Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model

Nature Medicine

Volumn 12, Issue 7, 2006, Pages 801-808

  McLaurin, JoAnne ^a   Kierstead, Meredith E ^a   Brown, Mary E ^a   Hawkes, Cheryl A ^a   Lambermon, Mark H L ^a   Phinney, Amie L ^a   Darabie, Audrey A ^a   Cousins, Julian E ^a   French, Janet E ^a   Lan, Melissa F ^a   Chen, Fusheng ^a   Wong, Sydney S N ^a   Mount, Howard T J ^a   Fraser, Paul E ^a,b   Westaway, David ^a   George Hyslop, Peter St ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; EPICYCLOHEXANEHEXOL; INOSITOL DERIVATIVE; OLIGOMER; SCYLLOCYCLOHEXANEHEXOL; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; CYCLOHEXANOL DERIVATIVE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; MOLECULAR WEIGHT; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEREOISOMERISM; SYNAPTIC TRANSMISSION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; MEMORY; PATHOLOGY; PHYSIOLOGY; SENILE PLAQUE; SYNAPSE; TRANSGENIC MOUSE;

MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; MEMORY; MICE; MICE, TRANSGENIC; NOOTROPIC AGENTS; PHENOTYPE; SENILE PLAQUES; SYNAPSES;

EID: 33745922350     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1423     Document Type: Article

References (35)

1. Selkoe, D.J. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J. Clin. Invest. 110, 1375-1381 (2002).
2. Glabe, C.C. Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Aβ. Subcell. Biochem. 38, 167-177 (2005).
3. McLaurin, J. & Chakrabartty, A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem. 271, 26482-26489 (1996).
4. McLaurin, J. & Chakrabartty, A. Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. Eur. J. Biochem. 245, 355-363 (1997).
5. Koppaka, V. & Axelson, P.M. Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes. Biochemistry 39, 10011-10016 (2000).
6. Mizuno, T. et al. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J. Biol. Chem. 274, 15110-15114 (1999).
7. Choo-Smith, L.P. & Surewicz, W.K. The interaction between Alzheimer amyloid beta (1-40) peptide and ganglioside GM1-containing membranes. FEBS Lett. 402, 95-98 (1997).
8. Yanagisawa, K. et al. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 1062-1066 (1995).
9. Auton, M. & Bolen, D.W. Predicting the energetics of osmolyte-induced protein folding/ unfolding. Proc. Natl. Acad. Sci. USA 102, 15065-15068 (2005).
10. McLaurin, J., Franklin, T., Chakrabartty, A. & Fraser, P.E. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J. Mol. Biol. 278, 183-194 (1998).
11. McLaurin, J., Goloumb, R., Jurewicz, A., Antel, J.P. & Fraser, P.E. Inositol stereo-isomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Aβ-induced toxicity. J. Biol. Chem. 275, 18495-18502 (2000).
12. Chishti, M.A. et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562-21570 (2001).
13. Janus, C. et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982 (2000).
14. Morris, R. Development of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47-60 (1984).
15. Klein, W.L. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as a new vaccine and drug targets. Neurochem. Int. 41, 345-352 (2002).
16. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
17. Spector, R. Myo-inositol transport through the blood-brain barrier. Neurochem. Res. 13, 785-787 (1988).
18. Uldry, M. et al. Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J. 20, 4467-4477 (2001).
19. Uldry, M. & Thorens, B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 447, 480-489 (2004).
20. Shetty, H.U. & Hollway, H.W. Assay of myo-inositol in cerebrospinal fluid and plasma by chemical ionization mass spectrometry of the hexaacetate derivative. Biol. Mass Spectrom. 23, 440-444 (1994).
21. McLaurin, J. et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263-1269 (2002).
22. Frenkel, D., Katz, O. & Solomon, B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. USA 97, 11455-11459 (2000).
23. Bard, F. et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against disease-like neuropathology. Proc. Natl. Acad. Sci. USA 100, 2023-2028 (2003).
24. Nicoll, J.A. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9, 448-452 (2003).
25. Hock, C. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554 (2003).
26. Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148-154 (2004).
27. Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
28. Fisher, S.K., Novak, J.E., & Agranoff, B.W. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J. Neurochem. 82, 736-754 (2002).
29. Vaucher, E. et al. Object recognition memory and cholinergic parameters in mice expressing human presenilin 1 transgenes. Exp. Neurol. 175, 398-406 (2002).
30. Mount, H.T. et al. Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia. J. Neurochem. 88, 1449-1454 (2004).
31. Wiltfang, J. et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481-496 (2002).
32. Haccou, P. & Mellis, E. Statistical Analysis of Behavioural Data 120-186 (Oxford Univ Press, Oxford, 1995).
33. Chen, F. et al. Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J. Biol. Chem. 275, 36794-36802 (2000).
34. Phinney, A. et al. No hippocampal neuron or synaptic bouton loss in learning-impaired aged β-amyloid precursor protein-null mice. Neuroscience 90, 1207-1216 (1999).
35. Hu, L. et al. The impact of Aβ-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience 121, 421-432 (2003).